Tenofovir Alafenamide Therapy Throughout Pregnancy in Mothers With Hepatitis B
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.70173 ↗Kurz gefasst
Kommentar in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Xingfei Pan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Guangdong Provincial Key Laboratory of Major Obstetric Diseases; Guangdong Provincial Clinical Research Center for…. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Pregnancy Complications, Infectious, Tenofovir, Antiviral Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Background
Mothers with chronic hepatitis B and advanced fibrosis may require antiviral therapy throughout pregnancy. Current guidelines recommend tenofovir disoproxil fumarate (TDF), which is unsuitable for mothers at risk of renal dysfunction or decreased bone mineral density.
Aims
This study aimed to evaluate the safety of tenofovir alafenamide (TAF) therapy during pregnancy.
Methods
Mothers with chronic hepatitis B treated with TAF or no therapy were retrospectively enrolled and categorised into three groups: (A) TAF‐first trimester, (B) TAF‐late trimester and (C) no treatment. Propensity score matching was applied to create comparable groups. Primary assessments included serious adverse events up to postpartum week 28, while secondary assessments examined predictors of such events and vertical transmission rates.
Results
Among 284 mothers, 160 were selected. No significant differences were observed in foetal loss, low birth weight, preterm delivery or congenital abnormalities between groups A and B, or between groups A and C. Other adverse events were similar across groups, except for a higher incidence of gestational diabetes in the TAF‐first trimester group. In vitro fertilisation was identified as the sole predictor of serious events. No infants were reported with hepatitis B virus infection at 28 weeks postpartum.
Conclusions
This study suggests that TAF treatment throughout pregnancy is safe for mothers with chronic hepatitis B and their infants. TAF therapy represents a viable treatment option for these mothers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Guangdong Provincial Key Laboratory of Major Obstetric Diseases; Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, The Third Affiliated Hospital, Guangzhou M…
- Department of Obstetrics and Gynecology, Department of Obstetrics, Guangdong Provincial Key Laboratory of Major Obstetric Diseases; Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology; Guangdong-…
- Department of Obstetrics and Gynecology, Guangdong Provincial Key Laboratory of Major Obstetric Diseases; Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology; Guangdong-Hong Kong-Macao Greater Ba…
- Guangzhou Medical University, Guangzhou, China.
- Division of Gastroenterology and Hepatology, Department of Medicine, NYU Langone Health, NYU Grossman School of Medicine, New York, USA.
ORCID-Profile: Calvin Q Pan
Zitieren
APA
Pan, X., Zhou, L., Hu, J., Zhai, P., Ou, X., He, F., & Pan, C. Q. (2025). Tenofovir Alafenamide Therapy Throughout Pregnancy in Mothers With Hepatitis B. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70173
Vancouver
Pan X, Zhou L, Hu J, Zhai P, Ou X, He F, et al. Tenofovir Alafenamide Therapy Throughout Pregnancy in Mothers With Hepatitis B. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70173
BibTeX
@article{Pan2025,
author = {Pan, Xingfei and Zhou, Liyang and Hu, Jing and Zhai, Panpan and Ou, Xueting and He, Fang and Pan, Calvin Q},
title = {Tenofovir Alafenamide Therapy Throughout Pregnancy in Mothers With Hepatitis B},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.70173}
}
EUVIMED